Divestment of portfolio of branded and generic products to Strides entities

Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma Pty Ltd (“Strides Australia”), a company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a portfolio of approximately 130 products for a consideration of approximately A$265 million (“the Australian Transaction”).

The portfolio of products in the Australian Transaction comprises a generic pharmaceutical business together with certain branded pharmaceutical assets. This portfolio recorded revenue of A$106 million and a direct contribution to profit before tax of A$26 million for the year ended 30 June 2014.

In a separate transaction, Aspen Global Incorporated (“AGI”), a company incorporated in Mauritius, has entered into an agreement with Strides Pharma Global Pte Limited (“Strides Singapore”), a company incorporated in Singapore, in terms whereof AGI will divest to Strides Singapore, a portfolio of six branded prescription products, for a consideration of approximately US$92 million. This portfolio recorded revenue of US$12 million and a direct contribution to profit before tax of US$10 million for the year ended 30 June 2014.

Strides Australia and Strides Singapore are wholly owned subsidiaries of Strides Arcolab Limited (“Strides”), a pharmaceutical company headquartered and publicly listed in India. Strides have a key focus on the development and manufacture of IP-led, niche pharmaceuticals products.

These transactions form part of Aspen’s communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity.

Aspen Seeks Drugs Acquisitions

Aspen Pharmacare Holdings Ltd., Africa’s largest generic-drugs maker, is looking for acquisitions and seeking to expand its infant nutrition business after international sales boosted full-year profit.

The Durban, South Africa-based company, which supplies medicines in more than 150 countries, is seeking purchases in China, Japan and Southeast Asia, Deputy Chief Executive Officer Gus Attridge said by phone on Wednesday. While Aspen “won’t walk away from any great opportunity,” the company is seeking to expand its infant-milk, anti-coagulant and women’s-health units, he said.

The company has spent more than $2 billion on acquisitions from drugmakers including GlaxoSmithKline Plc and Merck & Co. in the past three years to boost its portfolio of medicines and manufacturing sites. London-based Glaxo took a stake in the company’s Japanese unit in October to boost operations in that country.

Net income climbed 3.9 percent to 5.2 billion rand ($380 million) in the year through June, Aspen said in an earlier statement. That compares with a 5.16 billion-rand estimate of six analysts surveyed by Bloomberg. Sales increased 22 percent to 36.1 billion rand, boosted by a 46 percent gain in international revenue.

Profit margins at the South African unit were pressured by ongoing weakening of the rand relative to the U.S. dollar as well as high wage and energy-cost inflation.  Increased sales of low-margin antiretroviral drugs to South Africa’s government also suppressed margins, Attridge said.

In May, the company agreed to sell a drugs business to Dublin-based Endo International Plc for about $130 million and two pharmaceutical portfolios to units of Strides Arcolab Ltd. of India for $301 million. The majority of the proceeds have been earmarked for acquisitions.